Recent News

• 09.04.2025 - Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
• 09.04.2025 - Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
• 08.04.2025 - Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
• 08.04.2025 - Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
• 07.31.2025 - Q2 2025 Agios Pharmaceuticals Inc Earnings Conference Call
• 07.31.2025 - Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
• 07.31.2025 - Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 08.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.28.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.27.2025 - 144 Report of proposed sale of securities
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.08.2025 - 144 Report of proposed sale of securities
• 08.04.2025 - 8-K Current report
• 07.31.2025 - EX-99.1 EX-99.1
• 07.31.2025 - 8-K Current report